Nokia’s new Android-powered smartphones might arrive at MWC 2017

An official slide from a Nokia presentation delivered at the company’s recent Capital Markets Day confirms the “Nokia brand’s return to smartphones” in 2017. With the company previously tweeting to say its CEO Rajeev Suri will deliver a keynote speech at MWC 2017, it’s looking increasingly likely that we’ll see Nokia’s 2017 lineup of Android-powered smartphones in late February.

Of course, Suri’s keynote may not be centered on announcing the new devices, and indeed we may not see any new Nokia devices at the trade show, but considering the smartphone focus of MWC and Suri’s confirmed keynote, it’s hard not to assume otherwise.

Nokia’s return to smartphones has been eagerly anticipated, both by those nostalgic for the Nokia brand as well as by those anxious to see if Nokia tries to deliver on its traditional strengths – outstanding durability and phenomenal battery life – in an Android smartphone.

Nokia’s name may appear on the devices likely to arrive at MWC 2017, but they won’t actually be made by Nokia. Back in May the company announced it had reached an exclusive branding rights deal with a hastily-constructed consortium of ex-Nokia veterans.

HMD Global was put together virtually overnight in order to secure the rights to using the Nokia brand on smartphones when the licensing offer was first made public. Whatever happens at MWC in February, we’re going to be more pumped to see a Nokia phone than we have been since the late 90s.

Are you excited for a new Nokia smartphone? What do you think it’ll look like?

Comments

The Secret Science 02:The 30 Most Disturbing Human Experiments in History

Disturbing human experiments aren’t something the average person thinks too much about. Rather, the progress achieved in the last 150 years of human history is an accomplishment we’re reminded of almost daily. Achievements made in fields like biomedicine and psychology mean that we no longer need to worry about things like deadly diseases or masturbation as a form of insanity. For better or worse, we have developed more effective ways to gather information, treat skin abnormalities, and even kill each other. But what we are not constantly reminded of are the human lives that have been damaged or lost in the name of this progress. The following is a list of the 30 most disturbing human experiments in history. 30. The Tearoom Sex Study Sociologist Laud Humphreys often wondered about the men who commit impersonal sexual acts with one another in public restrooms. He wondered why “tearoom sex” — fellatio in public restrooms — led to the majority of homosexual arrests in ...

The Strange and Stranger Case of Wyndham Lathem

A Northwestern University plague researcher has been charged with a brutal murder. Here’s what we know about him. WIKIMEDIA, TONY WEBSTER O n July 27, The Chicago Tribune reported that there was an arrest warrant issued for Wyndham Lathem , a microbiologist at Northwestern University. The crime Lathem would later be charged with was brutal—26-year-old Trenton James Cornell-Duranleau, whose body was found in Lathem’s apartment, had been stabbed dozens of times. But Lathem was nowhere to be found. As events unfolded over the following days, it became clear he had fled from Chicago to California with a second suspect, 56-year-old Andrew Warren, a University of Oxford employee from the United Kingdom visiting the states. Along the way, the two men apparently made an anonymous $1,000 donation in Cornell-Duranleau’s name to the Lake Geneva Public Library and another donation for $5,610 to a Chicago health center. Lathem had also sent a video to fa...

Popular painkiller doesn’t have more heart risks than others, study claims

NEW ORLEANS — A long-awaited study on painkillers called nonsteroidal anti-inflammatory drugs, the most widely prescribed class of drugs in the world, has concluded that the three most commonly used carry a similar risk of cardiovascular complications. Yet critics say the study was too flawed to fairly compare them. Concerns about a type of NSAID called COX-2 inhibitors peaked in 2004 when the drug Vioxx was withdrawn from the market — a decision steeped in scandal because manufacturer Merck & Co had initially hidden data that would reveal the drug’s cardiovascular risks. A second COX-2 inhibitor, Pfizer Inc.’s Celebrex, was allowed to remain on the market with the condition that Pfizer conduct a study to prove that Celebrex was no worse than two older NSAIDs, naproxen and ibuprofen. The study lasted 10 years and enrolled more than 24,000 patients, but faced challenges. Doctors in European Union countries would not participate because they were worried a...

The Research

Search This Blog